AB-1005
DrugBilateral image-guided infusion of AAV2-GDNF into putamen, single dose
NCT Number: NCT07566429
The objective of this Phase 2, open-label, single group, one-time, fixed-dose study is to assess the safety and efficacy of bilateral intraputaminal infusion of AB-1005 (AAV2-GDNF gene therapy) in Japanese patients with moderate Parkinson's Disease (PD).
Trial opening soon.
Get Notified45 year–75 year
All sexes
Interventional
Phase 2
Nagoya Central Hospital - Neurosurgery, Nagoya, Aichi-ken, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
Time frame: Up to 18 months
Number and proportion of participants with at least one adverse event
Time frame: Up to 18 months
Contact information is provided by the study sponsor or research team.
Bayer
Industry
A Phase 2, Open-label, Single Group, Fixed-dose Study to Evaluate the Safety and Efficacy of a Single Bilateral Intraputaminal Administration of AB-1005 (AAV2-GDNF Gene Therapy) in Japanese Participants With Moderate Stage Parkinson's Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07824128
Alzheimer Disease, Basal Ganglia Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT07286994
Basal Ganglia Diseases, Behavior
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07804381
Basal Ganglia Diseases, Brain Diseases
View Trial DetailsNCT07764874
Basal Ganglia Diseases, Brain Diseases
Seoul, South Korea
View Trial Details